Introduction
Biomarkers for lung cancer have several potential clinical uses. They may be used for risk stratification, early lung cancer detection, optimal treatment selection, prognostication and monitoring for recurrence. Given the current dismal 5-year survival rate for lung cancer patients, all of these areas could benefit from the use of sensitive and specific, noninvasive, cost-effective biomarkers. Different markers, reflecting the biology of lung cancer progression from premalignancy to invasive lung cancer, may prove more useful for each of these areas. Here, we will discuss the current and potential uses of biomarkers for lung cancer diagnosis and treatment, progress in understanding the biology of lung cancer progression, and recent advances in the identification of lung cancer biomarkers.
Uses of lung cancer biomarkers
The persistent poor survival for lung cancer patients is largely attributable to late stage at diagnosis. The overall 5-year survival for nonsmall cell lung cancer (NSCLC) remains at only 15%; however, if the cancer is detected at stage IA the 5-year survival often exceeds 80% [1]. Recent publications have described the success of chest computed tomography screening in detecting early-stage lung cancer [2 ,3 ] . These have been nonrandomized trials and therefore have not shown an impact on lung cancer mortality. The survival improvements reported [2 ] may be due to lead-time bias or overdiagnosis of indolent cancers. Two randomized trials of computed tomography scan screening in the US and Europe are currently underway.
Undoubtedly computed tomography scans can detect small noncalcified nodules that may represent early lung cancers, but this technique is problematic. First, it has poor specificity because of the high prevalence of nonspecific benign pulmonary nodules [4] . In addition, computed tomography scans are costly and the necessity for repeated computed tomography scans to determine growth rates over time can expose patients to potentially harmful radiation [5] . Finally, we cannot predict which early lung cancers will progress and which will remain indolent for prolonged periods. Plasma or serum biomarkers could be a minimally invasive, cost-effective way to identify individuals at high risk for lung cancer and therefore suitable for computed tomography screening. Alternatively, biomarkers may differentiate benign noncalcified nodules from early lung cancers or small cancers which will remain indolent from those that are likely to progress. Even more tantalizing is the possibility that biomarkers may identify individuals with premalignant lesions, thereby opening the door to chemoprevention of lung cancer.
There is also a need for tests that can help clinicians choose the optimal treatment modality and assess response of the cancer to therapy. Once a lung cancer has been diagnosed, current treatment options depend on the pathological type and the stage of diagnosis. Biomarkers may more fully characterize tumors, determine metastatic potential and predict response to particular chemotherapeutic agents. Information on prognosis can assist patients and clinicians when considering treatment options. Currently, monitoring for recurrence after treatment consists of positron emission tomography and computed tomography scans. Serum markers have been used in conjunction with the imaging studies to assess response. Serum markers are generally less costly and less time consuming.
Biology of lung carcinogenesis
Progress in understanding the sequence of molecular changes underlying the progression from preneoplasia to invasive lung cancer has spurred research into biomarkers for early detection and into the possibility of personalizing treatment based on biomarker profiles. The known preneoplastic lesions of the bronchial epithelium are: squamous dysplasia and carcinoma in situ, which progress to squamous cell carcinoma; atypical adenomatous hyperplasia, which may precede adenocarcinoma; and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia, which may progress to carcinoid. No preneoplastic lesion has been identified for small cell carcinoma [6, 7] .
Alterations in gene expression and chromosome structure have been demonstrated in these preneoplastic lesions and the changes appear to be sequential -their frequency and number increase with increasing atypia. Some of the alterations found in preneoplastic lesions include: hyperproliferation and loss of cell cycle control; abnormalities in the p53 pathway, the ras genes and genes in the genomic region of 3p14.2; aberrant gene promoter methylation; increased vascular growth; altered extracellular matrix; decreased retinoic acid and retinoid X receptor expression; and altered expression of multiple proteins [7] [8] [9] .
Lung cancer biomarkers: currently in use
The following markers are clinically available in some areas, although the use of these markers for lung cancer detection or monitoring is not currently recommended or encouraged [10] .
Carcinoembryonic antigen (CEA) is an oncofetal protein not typically detected in adults. Increased production in cancer cells is caused by de-repression of CEA-encoding genes. In lung cancers where CEA is elevated, the levels may correlate with response to therapy. CEA is neither sensitive nor specific and is often elevated in smokers. CEA can be used along with other measures to screen for lung cancer recurrence and high levels may be predictive of poor survival [11] .
CYFRA 21-1 measures cytokeratin 19 fragments present in epithelial cells. It is associated with epithelial cell cancers, including NSCLCs, especially with squamous cell histology. The sensitivity of this marker for NSCLC varies between 23 and 70% [12 ] . This marker may, however, also be elevated in patients with benign lung diseases. CYFRA 21-1 does seem to correlate to disease response and prognosis, and therefore may be used in conjunction with other tests for prognostication and monitoring for recurrence [13] .
Squamous cell carcinoma antigen is a structural cytoplasmic protein. Its circulating concentration may be elevated in squamous cell carcinomas. The levels may also be elevated in skin diseases and inflammatory lung diseases. The published sensitivity for NSCLC ranges from 15 to 55%, with the highest sensitivity for squamous cell carcinoma. The levels may correlate with metastatic potential [12 ] .
Neuron-specific enolase, a glycolytic enzyme produced in central and peripheral neurons and malignant tumors of neuroectodermal origin, may be elevated in medullarythyroid cancer and small cell lung cancer. It is, however, also found in a variety of circulating cells and may be elevated in inflammatory diseases. Its sensitivity for detecting small cell lung cancer may be as high as 74% and elevated levels may correlate with shorter survival [14, 15] .
Progastrin-releasing peptide is the more stable biochemical precursor of gastrin-releasing peptide. Gastrin-releasing peptide is produced by neuroendocrine tissues of the gastrointestinal and respiratory tracts, stimulating the release of hormones. This peptide is sometimes used as a marker for small cell lung cancer, although it will also be increased in renal failure and some benign lung diseases. Its sensitivity for the detection of small cell lung cancer is in the range of 47-86% [12 ] . The level of progastrin-releasing peptide is not prognostic. Progastrinreleasing peptide and neuron-specific enolase may be used together to monitor response to therapy in small cell lung cancer [12 ,16] .
Tumor M2-pyruvate kinase is a dimeric form of pyruvate kinase over-represented in tumor cells. Levels are increased in multiple malignant diseases, as well as in some inflammatory conditions. Sensitivity for lung cancer ranges from 50 to 71%, with the highest sensitivity in adenocarcinomas [12 ] . This marker may also be useful in monitoring for relapse after treatment.
C-reactive protein (CRP) is increased in many inflammatory conditions, including cancer. Although not specific for lung cancer, levels of CRP may be useful in predicting prognosis. In a recent study, 7017 participants were followed for a mean of over 10 years [17 ] . High levels of CRP were associated with an increased risk of incident cancer and the association was strongest for lung cancer. Also, a CRP gene variation associated with decreased CRP levels was associated with increased risk of cancer. The authors concluded that both chronic inflammation and impaired defense mechanisms resulting in chronic inflammation might predispose to lung cancer.
Other markers
Levels of lactate dehydrogenase may correlate with disease extent in NSCLC [12 ] . Carbohydrate antigen 125, a glycoprotein that arises in fetal tissue, is used mainly in detection of ovarian carcinoma, but may also be elevated in adenocarcinomas and large cell carcinomas of the lung. Neural cell adhesion molecule is known to be involved in adhesion and aggregation processes during metastasis. High levels have been found in small cell lung cancer [12 ] .
Panels of markers, including some combination of CEA, CYFRA21-1, squamous cell carcinoma antigen and neuron-specific enolase, are sometimes used to improve sensitivity for lung cancer detection. These panels lose specificity, however, and are not recommended for primary lung cancer surveillance. They may have some utility in monitoring for relapse after therapy.
Epidermal growth factor receptor
With the newer 'targeted' lung cancer therapy there is growing interest in molecular markers that are more specific for predicting response and prognosis. Epidermal growth factor receptor (EGFR) and its intracellular tyrosine kinase have been investigated for their role in the biology of NSCLC. Agents that target this pathway are currently in use. These include small molecules, such as gefitinib and erlotinib, which inhibit tyrosine kinase, as well as monoclonal antibodies against extracellular EGFR, such as cetuximab and panitumumab. The presence of the mutated EGFR has been associated with response to the tyrosine kinase inhibitors. More recent studies indicate there may be other important parameters, such as EGFR copy numbers and mRNA expression [18 ] . Both EGFR mutations and EGFR copy numbers can be detected in biopsy specimens, and may aid the clinician in choosing therapeutic agents.
Lung cancer biomarkers: potential
Given the many different genetic and epigenetic changes involved in malignant transformation in lung cancer, it is clear that there are innumerable potential biomarkers. With progress in understanding the biology of lung carcinogenesis, the development of high-throughput techniques for biomarker discovery and increased focus on early detection of lung cancer, the field of lung cancer biomarkers has undergone a minor explosion. No biomarker has yet been shown to have adequate sensitivity, specificity and reproducibility to be validated as a biomarker for the early detection of lung cancer. We provide an overview of some promising recent studies of lung cancer biomarkers.
Circulating DNA Levels of circulating cell-free DNA in plasma and serum are generally reported to be higher in patients with cancer than in healthy controls [19 ] . This assay in itself is not a useful biomarker as the levels vary considerably according to the type and stage of cancer and the technique of measuring DNA. As the source of the increased DNA in lung cancer is thought to be apoptotic or necrotic tumor cells that release DNA into the circulation [20] , there is growing interest in finding more specific markers using this circulating DNA. The circulating DNA in lung cancer patients exhibits genetic and epigenetic changes typical of the tumor (chromosome loss, oncogene activation and tumor suppressor gene inactivation by methylation) [21, 22] .
Genetic changes
Since loss of genetic material from chromosome 3p is one of the earliest genetic changes occurring during bronchial carcinogenesis, several studies have looked at whether these changes -microsatellite instability and loss of heterozygosity -could be found in circulating DNA [23] . In general, these genetic alterations have been found in circulating DNA of 27-88% of lung cancer patients [19 ] . When multiple markers are combined, the sensitivity can be increased, but often at the cost of specificity.
The genetic mutations most commonly studied as possible lung cancer biomarkers are K-ras, and p53, since these are well-characterized common mutations in human lung cancer and preneoplasia. K-ras mutations in circulating DNA have been found in 20-30% of lung cancer patients, p53 mutations in 27% [24 ] . Reports conflict on whether the presence of these mutations predicts resistance to chemotherapy.
Gene hypermethylation
Methylation of promoters in multiple different tumor suppressor genes occurs early in the development of lung cancer. Hypermethylation of gene promoter regions is associated with silencing of transcription. Silencing by hypermethylation affects genes involved in all aspects of normal cell function, and is a critical trigger for malignant transformation and progression [8] . Methylation can be detected by methylation-specific polymerase chain reaction analysis. In the methylation-specific polymerase chain reaction, bisulfite is used to convert all unmethylated (but not methylated) cytosines to uracil, and then amplification is performed with primers specific for methylated versus unmethylated DNA.
Promoter methylation has become an active area of research. In previous studies, aberrant methylation of p16 INK4a , APC, TMS1, RASSF1 and DAPK [19 ,25-28] have been reported in lung cancer. More recently, Belinsky et al. [29 ] reported that hypermethylation of the promoter region of multiple different genes in the blood and sputum is associated with lung cancer, and may even precede the clinical diagnosis of lung cancer. Other recent studies report aberrant promoter methylation in lung cancer of PRSS3 (serine protease family member-trypsinogen IV -a putative tumor suppressor gene) [30] , human DAB2 interactive protein gene [31] and apoptosis-associated speck-lick protein containing a CARD [32 ] . Hypermethylation of p16 and FHIT genes may be associated with an increased risk of lung cancer recurrence after therapy [33, 34 ].
Investigators have also looked at methylation in other body fluids and tissues. In bronchoalveolar lavage, methylation of p16, RASSF1A, H-cadherin and RARb was associated with the presence of lung cancer, whereas FHIT methylation seemed to be related to tobacco exposure [35] . Using bronchial aspirates, RASSF1A promoter hypermethylation was found in 88% of small cell lung cancer patients and 28% of NSCLC patients. No hypermethylation was found in subjects with benign lung disease [36 ] . In other studies, this group found aberrant promoter methylation of APC [37] , p16 and RARB2 [38] in bronchial aspirates from lung cancer patients. They report a sensitivity of 69% and specificity of 87% in the detection of lung cancer using this combination of genes.
A high-throughput global expression profiling approach has been used to try to identify new cancer-specific methylation markers. Applying this technique to multiple lung cancer cell lines, 132 genes that had been suppressed by methylation were identified. The investigators confirmed that these genes are expressed in normal lung, but often not in companion primary lung cancers. They found that seven of these loci were also commonly methylated in breast, colon and prostate cancers [39 ] .
Ehrich et al. [40 ] also recently reported the use of a new quantitative DNA methylation analysis technology to complete a large-scale cytosine methylation profiling study and thereby perhaps identify new methylation markers. They analyzed methylation at 47 different gene promoter regions in lung tumor tissue and adjacent normal lung from 96 lung cancer patients. Using a new technique that combines a method of peptide profiling, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, of methylation-dependent sequence changes introduced by bisulfite treatment, they were able to identify six genes with statistically significant differences in methylation in lung cancer tissues compared with normal tissues. These studies demonstrate that with the use of new techniques, high-throughput analysis of methylation status at multiple different promoter regions is possible.
Methylation-induced repression of target genes depends on suppressor of variegation 3-9 homolog 2 (SUV39H2). A recent study in South Korea found that a novel single nucleotide polymorphism of this histone methyltransferase was associated with a significant increase in lung cancer risk [41 ] .
Gene expression and proteins
Many investigators are looking at individual blood and sputum proteins as possible biomarkers for lung cancer. Examples of some recent studies follow. hnRNPB1, an RNA-binding protein involved in mRNA transportation and RNA mutation, is common in squamous cell carcinoma of the lung. Expression in the sputum has been correlated with risk of lung cancer development in certain populations, and the protein has been found to be overexpressed in early-stage lung cancer. A recent study of hnRNPB1 levels in plasma of lung cancer patients found that levels were increased in 46% of cancer patients compared with 12% of controls [42] .
Human telomeres function as a protective structure capping the ends of chromosomes. Dysfunction plays an important role in cancer initiation and progression. Human telomerase catalytic component (hTERT) is known to be elevated in cancers and EGFR is often increased in lung cancer. Miura et al. [43 ] measured hTERT and EGFR mRNA in 112 lung cancer patients and 80 controls, using quantitative one-step real-time reverse transcriptionpolymerase chain reaction. The copy number of serum hTERT mRNA correlated with tumor stage, metastasis and recurrence, and the copy number decreased after treatment. The authors reported a sensitivity and specificity of 89 and 73% for hTERT, and 71 and 80% for EGFR. Expression of RAP1, a gene that helps regulate telomere stability, was associated with improved survival in lung cancer patients (51 vs.15 months) [44 ] .
Survivin is a protein that inhibits apoptosis and promotes mitosis. The amount of nuclear survivin in tumor tissue may predict recurrence and poor survival in patients with resected NSCLC [45, 46] . Patients with nuclear survivin also had worse survival. Osteopontin overexpression has been found in both tissue and serum in lung cancer patients, and may be associated with more aggressive disease [47] . Fas-associated death domain inactivates NF-kB, and is associated with overexpression of cyclins D1 and B1, thereby affecting the cell cycle. Increased phosphorylated Fas-associated death domain mRNA and protein was associated with poor survival in lung cancer [48] . Functional polymorphisms of matrix metalloproteinase-9 have been associated with risk of lung cancer and recurrence [49] . Increased soluble E-cadherin was found in lung cancer patients [50] .
Proteomics and genomics
In 2007, Chen et al. [51 ] reported the results of a genomic study of lung cancer outcome. They performed microarray analysis of tumor tissue from patients with early-stage lung cancer who underwent surgical resection and identified 16 genes that were associated with improved survival. Five of these genes were then confirmed by reverse transcription-polymerase chain reaction: dual specificity phosphatase 6, monocyte to macrophage differentiation associated protein, signal transducer and activator of transcription 1, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3, and lymphocyte-specific protein tyrosine kinase. Patients with a high-risk gene signature were three to four times more likely to die of any cause within 5 years after surgery. Future randomized clinical trials may validate predicting response to particular agents based on such genetic profiling.
Proteomic studies in lung cancer have used two approaches: protein profiling, where patterns of protein expression are used to identify lung cancer and the actual proteins involved may not be known, and proteomic techniques to identify individual proteins that may serve as markers for lung cancer. One group has used matrixassisted laser desorption/ionization time-of-flight mass spectrometry and identified two proteins, serum amyloid A and macrophage migration inhibitory factor, as increased in lung cancer. Levels of these proteins did not predict outcome [52] . In a follow-up study, enzyme-linked immunosorbent assay analysis confirmed that serum amyloid A was increased in lung cancer patients, but macrophage-inhibitory factor levels did not differentiate lung cancer patients from subjects with other diseases [53] .
Several studies have used the surface-enhanced laser desorption/ionization time-of-flight technique to identify a pattern of protein peaks in the blood that could differentiate cancer patients from controls [54] . In a recent study investigators analyzed blood from 158 lung cancer patients and 50 controls, and chose a pattern of five protein peaks that could diagnose NSCLC, with a reported sensitivity of 91.4% in their test set [55] .
Autoimmunity
The presence of malignant cells can activate the immune system and cancer has been shown to induce autoimmunity to autologous cellular antigens [56] . Many of the target antigens are cellular proteins, whose deregulation or aberrant expression could lead to tumorigenesis. This systemic response to the tumor provides an opportunity to detect cancers at an early stage. Numerous immunogenic tumor-associated antigens have been identified using serological analysis of recombinant cDNA expression libraries of human tumors with autologous serum [57] . Autoantibodies to some of these antigens have been found in patients with lung cancers [58, 59] . One prospective study is looking at anticyclin B1 serum antibody as a possible diagnostic and prognostic marker in patients enrolled in a longitudinal lung cancer screening study [60] .
Owing to the heterogeneity of the immune system, as well as of lung cancer, it is unlikely that reactivity to any single tumor-associated antigen will identify all lung cancers. Microarray analysis allows for the evaluation of multiple different tumor-associated antigens simultaneously. The microarrays can be spotted with tumor proteins and then hybridized to lung cancer patients' serum. Using this technique, Qiu et al. [61] reported reactivity patterns that might identify lung cancer patients. Alternatively, the microarray can be spotted with antibodies to known tumor antigens and then hybridized to patients' sera to identify circulating tumor-associated antigens. Using this technique, Gao et al. [62] identified a distinctive serum protein profile in lung cancer patients compared with controls.
Other molecular markers
The cytokinesis-block micronucleus assay is a biomarker for genomic instability. It can be used to predict cancer risk based on numbers of micronuclei, nucleoplasmic bridges and nuclear buds. This assay is extremely sensitive to the genetic damage induced by NNK (a tobacco carcinogen) and may serve as a predictor of lung cancer risk [63 ] .
Many carcinogens exert their effects through the formation of DNA adducts by metabolically activated intermediates. Detecting the presence of these adducts in human tissues is a tool for studies of cancer risk [64] . Mitochondrial DNA has been proposed as a cancer biomarker. Jakupciak et al. [65] recently reported a rapid and high-throughput sequencing method for the detection of sequence variants in mitochondrial DNA.
An intriguing idea is the use of markers in the exhaled breath to diagnose lung cancer. Some studies have reported that dogs are able to distinguish breath samples from patients with lung cancer from healthy controls with great accuracy [66 ] . Volatile organic compounds, mainly alkanes and aromatic compounds, are preferentially produced and exhaled by lung cancer patients. Poli et al. [67] reported that the measurement of a combination of 13 volatile organic compounds in the exhaled breath allowed correct classification of lung cancer cases in 80% of cases.
Wang et al. [68] combined multiple DNA markers in the plasma and sputum to try to increase their sensitivity and specificity. They looked at promoter hypermethylation of three tumor suppressor genes by the methylation-specific polymerase chain reaction, and the instability of eight microsatellite markers by loss of heterozygosity and microsatellite instability analyses in lung tumor tissues and matched sputum specimens from 79 lung cancer patients. The authors selected seven biomarkers, loss of heterozygosity of D9S286, D9S942, GATA49D12 and D13S170, microsatellite instability of D9S942, and methylation of p16 INK4a and RARb, from the sputum analyses as the most sensitive and specific combination of markers for the detection of lung cancer.
Conclusion
The development of noninvasive lung cancer biomarkers could revolutionize the diagnosis and treatment of lung cancer. Early diagnosis is crucial to decreasing lung cancer mortality and personalized therapy based on genetic or functional markers may improve response to treatment. Lung cancer biomarkers may allow us to identify populations who would benefit from computed tomography screening, may differentiate individuals with benign pulmonary nodules from those with early malignancies and may allow for personalization of lung cancer treatment based on tumor characteristics.
Significant advances in our understanding of the molecular and genetic changes involved in lung carcinogenesis have provided the basis for many investigations of possible lung cancer biomarkers. The development of new and improved high-throughput technologies raises the potential for great strides in biomarker discovery. Over the last few years, research on lung cancer biomarkers has proliferated. Many studies report high sensitivity and specificity. These studies are, however, often troubled by small size, a lack of reproducibility or inconsistent controls between studies. All of the biomarkers identified so far must be validated in larger clinical cohorts.
The field of lung cancer biomarkers is progressing rapidly. The development of biomarkers for prognostication and personalization of therapy after diagnosis seems imminent, and there is hope for the development of practical biomarkers for the early detection of lung cancer in the foreseeable future.
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